Scott E. Wolkenberg
Scott E. Wolkenberg has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Craig W. Lindsley
Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., PO Box 4, West Point, PA 19486, USA
3 shared publicationsGeorge D. Hartman
Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., PO Box 4, West Point, PA 19486, USA
3 shared publicationsZhijian Zhao
Department of Medicinal Chemistry, Global Structural Biology, Chemical Modeling and Informatics, and Department of Neuroscience Research, Merck Research Laboratories , Sumneytown Pike, West Point, Pennsylvania 19486, United States
3 shared publicationsIulia I. Strambeanu
Discovery Chemistry, Janssen Research & Development LLC, 1400 McKean Road, Spring House, Pennsylvania 19477, United States
2 shared publications- James C. Barrow
Lieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States
2 shared publications James J. Mulhearn
Department of Medicinal Chemistry, Global Structural Biology, Chemical Modeling and Informatics, and Department of Neuroscience Research, Merck Research Laboratories , Sumneytown Pike, West Point, Pennsylvania 19486, United States
2 shared publications
Latest Publications
- 22 May 2023
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (6) , 853-859
Enabling Deoxygenative C(sp2)-C(sp3) Cross-Coupling for Parallel Medicinal Chemistry
Herein we report the development of an automated deoxygenative C(sp2)-C(sp3) coupling of aryl bromide with alcohols to enable parallel medicinal chemistry. Alcohols are among the most diverse and abundant building blocks, but their usage as alkyl precursors has been limited. Although metallaphotoredox deoxygenative coupling is becoming a promising strategy to form C(sp2)-C(sp3) bond, the reaction setup limits its widespread application in library synthesis. To achieve high throughput and consistency, an automated workflow involving solid-dosing and liquid-handling robots has been developed. We have successfully demonstrated this high-throughput protocol is robust and consistent across three automation platforms. Furthermore, guided by cheminformatic analysis, we examined alcohols with comprehensive chemical space coverage and established a meaningful scope for medicinal chemistry applications. By accessing the rich diversity of alcohols, this automated protocol has the potential to substantially increase the impact of C(sp2)-C(sp3) cross-coupling in drug discovery.
- 22 May 2023
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 14 (6) , 853-859
Enabling Deoxygenative C(sp2)-C(sp3) Cross-Coupling for Parallel Medicinal Chemistry
Herein we report the development of an automated deoxygenative C(sp2)-C(sp3) coupling of aryl bromide with alcohols to enable parallel medicinal chemistry. Alcohols are among the most diverse and abundant building blocks, but their usage as alkyl precursors has been limited. Although metallaphotoredox deoxygenative coupling is becoming a promising strategy to form C(sp2)-C(sp3) bond, the reaction setup limits its widespread application in library synthesis. To achieve high throughput and consistency, an automated workflow involving solid-dosing and liquid-handling robots has been developed. We have successfully demonstrated this high-throughput protocol is robust and consistent across three automation platforms. Furthermore, guided by cheminformatic analysis, we examined alcohols with comprehensive chemical space coverage and established a meaningful scope for medicinal chemistry applications. By accessing the rich diversity of alcohols, this automated protocol has the potential to substantially increase the impact of C(sp2)-C(sp3) cross-coupling in drug discovery.
- 20 June 2022
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 13 (7) , 1182-1190
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation
A platform to accelerate optimization of proteolysis targeting chimeras (PROTACs) has been developed using a direct-to-biology (D2B) approach with a focus on linker effects. A large number of linker analogs-with varying length, polarity, and rigidity-were rapidly prepared and characterized in four cell-based assays by streamlining time-consuming steps in synthesis and purification. The expansive dataset informs on linker structure-activity relationships (SAR) for in-cell E3 ligase target engagement, degradation, permeability, and cell toxicity. Unexpected aspects of linker SAR was discovered, consistent with literature reports on "linkerology", and the method dramatically speeds up empirical optimization. Physicochemical property trends emerged, and the platform has the potential to rapidly expand training sets for more complex prediction models. In-depth validation studies were carried out and confirm the D2B platform is a valuable tool to accelerate PROTAC design-make-test cycles.
- 20 June 2022
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 13 (7) , 1182-1190
Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation
A platform to accelerate optimization of proteolysis targeting chimeras (PROTACs) has been developed using a direct-to-biology (D2B) approach with a focus on linker effects. A large number of linker analogs-with varying length, polarity, and rigidity-were rapidly prepared and characterized in four cell-based assays by streamlining time-consuming steps in synthesis and purification. The expansive dataset informs on linker structure-activity relationships (SAR) for in-cell E3 ligase target engagement, degradation, permeability, and cell toxicity. Unexpected aspects of linker SAR was discovered, consistent with literature reports on "linkerology", and the method dramatically speeds up empirical optimization. Physicochemical property trends emerged, and the platform has the potential to rapidly expand training sets for more complex prediction models. In-depth validation studies were carried out and confirm the D2B platform is a valuable tool to accelerate PROTAC design-make-test cycles.
- 11 February 2021
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 12 (3) , 343-350
Trends in Hit-to-Lead Optimization Following DNA-Encoded Library Screens
DNA-encoded library (DEL) screens have emerged as a powerful hit-finding tool for a number of biological targets. In this Innovations article, we review published hit-to-lead optimization studies following DEL screens. Trends in molecular property changes from hit to lead are identified, and specific optimization tactics are exemplified in case studies. Across the studies, physicochemical property and structural changes post-DEL screening are similar to those which occur during hit-to-lead optimization following high throughputscreens (HTS). However, unique aspects of DEL—the combinatorial synthetic methods which enable DEL synthesis and the linker effects at the DNA attachment point—impact the strategies and outcomes of hit-to-lead optimizations.
- 11 February 2021
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 12 (3) , 343-350
Trends in Hit-to-Lead Optimization Following DNA-Encoded Library Screens
DNA-encoded library (DEL) screens have emerged as a powerful hit-finding tool for a number of biological targets. In this Innovations article, we review published hit-to-lead optimization studies following DEL screens. Trends in molecular property changes from hit to lead are identified, and specific optimization tactics are exemplified in case studies. Across the studies, physicochemical property and structural changes post-DEL screening are similar to those which occur during hit-to-lead optimization following high throughputscreens (HTS). However, unique aspects of DEL—the combinatorial synthetic methods which enable DEL synthesis and the linker effects at the DNA attachment point—impact the strategies and outcomes of hit-to-lead optimizations.
- 6 December 2018
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (1) , 56-61
Reducing Limitation in Probe Design: The Development of a Diazirine-Compatible Suzuki–Miyaura Cross Coupling Reaction
- 6 December 2018
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (1) , 56-61
Reducing Limitation in Probe Design: The Development of a Diazirine-Compatible Suzuki–Miyaura Cross Coupling Reaction
- 1 February 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (4) , 1062-1069
Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics
- 1 February 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (4) , 1062-1069
Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics
- 26 January 2015
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 6 (3) , 318-323
Synthesis and Evaluation of Heterocyclic Catechol Mimics as Inhibitors of Catechol-O-methyltransferase (COMT)
3-Hydroxy-4-pyridinones and 5-hydroxy-4-pyrimidinones were identified as inhibitors of catechol-O-methyltransferase (COMT) in a high-throughput screen. These heterocyclic catechol mimics exhibit potent inhibition of the enzyme and an improved toxicity profile versus the marketed nitrocatechol inhibitors tolcapone and entacapone. Optimization of the series was aided by X-ray cocrystal structures of the novel inhibitors in complex with COMT and cofactors SAM and Mg2+. The crystal structures suggest a mechanism of inhibition for these heterocyclic inhibitors distinct from previously disclosed COMT inhibitors.
- 26 January 2015
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 6 (3) , 318-323
Synthesis and Evaluation of Heterocyclic Catechol Mimics as Inhibitors of Catechol-O-methyltransferase (COMT)
3-Hydroxy-4-pyridinones and 5-hydroxy-4-pyrimidinones were identified as inhibitors of catechol-O-methyltransferase (COMT) in a high-throughput screen. These heterocyclic catechol mimics exhibit potent inhibition of the enzyme and an improved toxicity profile versus the marketed nitrocatechol inhibitors tolcapone and entacapone. Optimization of the series was aided by X-ray cocrystal structures of the novel inhibitors in complex with COMT and cofactors SAM and Mg2+. The crystal structures suggest a mechanism of inhibition for these heterocyclic inhibitors distinct from previously disclosed COMT inhibitors.
- 1 May 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (9) , 2646-2649
High concentration electrophysiology-based fragment screen: Discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors
- 1 May 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (9) , 2646-2649
High concentration electrophysiology-based fragment screen: Discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors
- 11 March 2011
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (7) , 2351-2358
Design, Synthesis, and Evaluation of Novel 3,6-Diaryl-4-aminoalkoxyquinolines as Selective Agonists of Somatostatin Receptor Subtype 2
Agonists of somatostatin receptor subtype 2 (sst2) have been proposed as therapeutics for the treatment of proliferative diabetic retinopathy and exudative age-related macular degeneration. An HTS screen identified 2-quinolones as weak agonists of sst2, and these were optimized to provide small molecules with sst2 binding and functional potency comparable to peptide agonists. Agonist 21 was shown to inhibit rat growth hormone secretion following systemic administration and to inhibit ocular neovascular lesion formation after local administration.
- 11 March 2011
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (7) , 2351-2358
Design, Synthesis, and Evaluation of Novel 3,6-Diaryl-4-aminoalkoxyquinolines as Selective Agonists of Somatostatin Receptor Subtype 2
Agonists of somatostatin receptor subtype 2 (sst2) have been proposed as therapeutics for the treatment of proliferative diabetic retinopathy and exudative age-related macular degeneration. An HTS screen identified 2-quinolones as weak agonists of sst2, and these were optimized to provide small molecules with sst2 binding and functional potency comparable to peptide agonists. Agonist 21 was shown to inhibit rat growth hormone secretion following systemic administration and to inhibit ocular neovascular lesion formation after local administration.
- 1 February 2010
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 10 (2) , 170-186
Recent Progress in the Discovery of Non-Sarcosine Based GlyT1 Inhibitors
The simple amino acid glycine is implicated in both inhibitory and excitatory neurotransmission in mammalian central nervous system, and it modulates excitatory neurotransmission through its role as a necessary co-agonist for glutamatergic N-methyl-D-aspartate (NMDA) receptors. Given the involvement of NMDA receptor-mediated neurotransmission in complex cerebral processes such as cognition, pharmacological manipulation of extracellular synaptic glycine biology is an active area of pharmaceutical research to develop novel treatments for neuropsychiatric disorders. A key component of cerebral glycine metabolism is the glycine transporter type 1 (GlyT1) and elevation of extracellular synaptic glycine concentration by blockade of GlyT1 has been hypothesized to potentiate NMDA receptor function in vivo and to represent a rational approach for the treatment of schizophrenia and cognitive disorders. The present article will review the wealth of scientific evidence supporting that hypothesis and the medicinal chemistry effort by many pharmaceutical companies and academic institutions to develop potent and selective GlyT1 inhibitors.
- 1 February 2010
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 10 (2) , 170-186
Recent Progress in the Discovery of Non-Sarcosine Based GlyT1 Inhibitors
The simple amino acid glycine is implicated in both inhibitory and excitatory neurotransmission in mammalian central nervous system, and it modulates excitatory neurotransmission through its role as a necessary co-agonist for glutamatergic N-methyl-D-aspartate (NMDA) receptors. Given the involvement of NMDA receptor-mediated neurotransmission in complex cerebral processes such as cognition, pharmacological manipulation of extracellular synaptic glycine biology is an active area of pharmaceutical research to develop novel treatments for neuropsychiatric disorders. A key component of cerebral glycine metabolism is the glycine transporter type 1 (GlyT1) and elevation of extracellular synaptic glycine concentration by blockade of GlyT1 has been hypothesized to potentiate NMDA receptor function in vivo and to represent a rational approach for the treatment of schizophrenia and cognitive disorders. The present article will review the wealth of scientific evidence supporting that hypothesis and the medicinal chemistry effort by many pharmaceutical companies and academic institutions to develop potent and selective GlyT1 inhibitors.
- 1 July 2008
- Vol. 11 (4) , 446-57
Recent progress in the discovery of selective, non-peptide ligands of somatostatin receptors.
Over the past 5 years, researchers in industry and academia have reported the design, synthesis and evaluation of many non-peptide ligands for somatostatin receptors. Structurally diverse agonists and antagonists that, in some cases, exhibit selectivity among the somatostatin receptor subtypes have been published. These agents represent research tools for the clarification of individual receptor pharmacology and are also promising leads for the development of orally active therapeutics for endocrine disorders, proliferative diseases and mood disorders. This review summarizes recent developments in the identification of non-peptide ligands of somatostatin receptors.
- 1 July 2008
- Vol. 11 (4) , 446-57
Recent progress in the discovery of selective, non-peptide ligands of somatostatin receptors.
Over the past 5 years, researchers in industry and academia have reported the design, synthesis and evaluation of many non-peptide ligands for somatostatin receptors. Structurally diverse agonists and antagonists that, in some cases, exhibit selectivity among the somatostatin receptor subtypes have been published. These agents represent research tools for the clarification of individual receptor pharmacology and are also promising leads for the development of orally active therapeutics for endocrine disorders, proliferative diseases and mood disorders. This review summarizes recent developments in the identification of non-peptide ligands of somatostatin receptors.